Lyra Therapeutics (LYRA) Cash & Equivalents (2019 - 2025)

Lyra Therapeutics (LYRA) has reported Cash & Equivalents for 7 consecutive years, with $15.9 million the latest figure, recorded in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $15.9 million, down 60.83% year-over-year; the trailing twelve-month figure through Dec 2025 was $15.9 million (down 60.83% YoY), and the FY2025 annual result was $15.9 million, down 60.83% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $15.9 million, down from $22.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $122.1 million in Q2 2022, with the low at $15.9 million in Q4 2025.
• A 5-year average of $43.7 million and a median of $33.9 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 87.55% in 2021 and plunged 76.35% in 2023, its largest moves.
• Lyra Therapeutics' Cash & Equivalents stood at $46.1 million in 2021, then retreated by 26.33% to $33.9 million in 2022, then tumbled by 30.04% to $23.7 million in 2023, then jumped by 70.89% to $40.6 million in 2024, then sank by 60.83% to $15.9 million in 2025.
• The last three Cash & Equivalents figures came in at $15.9 million (Q4 2025), $22.1 million (Q3 2025), and $40.6 million (Q4 2024), per Business Quant data.